Walleye Capital’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
Walleye Capital's AXSM Position: Q3 2026 in Review
Walleye Capital reduced its Axsome Therapeutics (AXSM) stake by 46% in Q3 2026, selling an estimated $173K and leaving 920 shares worth $170K. The position accounts for ﹤0.01% of the portfolio, ranked #4917.
Walleye Capital first reported a position in AXSM in Q3 2018 and has held it in 15 quarters since. The position peaked at $17.6M in Q4 2019. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- Walleye Capital held 920 shares of Axsome Therapeutics worth $170K as of Q3 2026.
- Walleye Capital sold 796 Axsome Therapeutics shares in Q3 2026, an estimated $173K.
- Axsome Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #4917 holding.
- Walleye Capital first reported a position in Axsome Therapeutics in Q3 2018 and has held it in 15 quarters since.
- Walleye Capital's Axsome Therapeutics position peaked at $17.6M in Q4 2019.
- 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.